Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5073221 | 0.94 | RIPK1 (0.33) | RIPK1 | |
| SCHEMBL8391276 | 0.82 | — | — | |
| SCHEMBL8075407 | 0.72 | PPARA (0.36) | RIPK1 | |
| SCHEMBL8070765 | 0.71 | PPARA (0.33) | RIPK1 | |
| SCHEMBL28914670 | 0.71 | RIPK1 (0.38) | RIPK1 | |
| SCHEMBL8559419 | 0.71 | RIPK1 (0.43) | RIPK1 | |
| SCHEMBL9569520 | 0.70 | ATM (0.30) | — | |
| SCHEMBL19305259 | 0.69 | — | — | |
| SCHEMBL706844 | 0.68 | RIPK1 (0.35) | RIPK1 | |
| SCHEMBL5865014 | 0.68 | RIPK1 (0.33) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | MSD K.K. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7388010-B2 | Quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-06-17 | — | — | US | disclosed |
| US-20060019959-A1 | Novel quinoxalinone derivatives | BANYU PHARMACEUTICAL CO., LTD. TSUKUBA RESEARCH INSTITUTE (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1557418-A1 | NOVEL QUINOXALINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-27 | — | — | EP | disclosed |
| EP-0575494-A4 | — | — | 1994-04-20 | — | — | EP | disclosed |
| EP-0575494-A1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-12-29 | — | — | EP | disclosed |
| WO-1992016104-A1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137597-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB7 | RIPK1 3518/4885CTSK 3907/4885CTSL 4171/4885 |
| US-20060019959-A1 | Novel quinoxalinone derivatives | NDUFB1, NDUFB6, NDUFB11 | RIPK1 3544/4885CTSK 3865/4885CTSL 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.